Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office (“CIPO“) has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.

Canntab’s Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O’Hara LLP said, “The allowance of Canntab’s patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab’s innovative tableting technology and validates the years of research and development the company has conducted. The Company now has patent protection in Canada and the USA providing an international scope to the Company’s expanding portfolio of issued patents.”


Canntab believes its hard pill formulations are superior to all other medical CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing, as opposed to the widely available gel caps and capsule products from other suppliers.

Larry Latowsky, CEO of Canntab said, “This is another major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace. Intellectual property is at the root of our value proposition and, having been granted our first Canadian patent and our second patent overall in less than 5 months, further confirms our leading position as the go to company for precise dosage and pharmaceutical grade tablets for the medical market containing THC, CBD or any combination of THC and CBD.”  Mr. Latowsky added “we are particularly pleased with the opportunities that are being presented for us to provide solutions to the USA market with the anticipated regulatory changes contemplated by the Biden Administration which we anticipate will allow us faster access to the largest medical cannabis market in the world”.

To further advance our IP, Canntab intends to prove greater bio-availability through a blood level study at a third party Clinical Research Organization (“CRO”). This study is currently in the planning phase and Canntab will provide further details on timing and results as soon as this information becomes available. Going forward, Canntab is able to provide extended-release formulations, whether the intended use is for medical, recreational or nutraceutical purposes, which will make it easier for doctors, patients, and the average consumer to make Canntab products their preferred cannabinoid delivery option.

Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed. Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/ sustained-release pharmaceutical grade delivery systems.

On September 21, 2020 Canntab had announced that pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) had issued U.S. Patent No. 10,772,837 to Canntab, titled “Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038. The patent granted was for Canntab’s bi-layer or multi-layer tablets consisting of both Instant Release (“IR”) and Extended Release (‘XR”) formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world.  These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Cautionary Statements

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include, but are not limited to, those regarding anticipated regulatory changes in the United States allowing the Company to access that market quicker than initially anticipated, and the Company being able to provide greater bio-availability through a blood level study at a third party Clinical Research Organization. The material factors or assumptions used to develop these forward-looking statements include that the federal administration in the United States will repeal legislation rendering the use and possession of cannabis illegal for any purpose, including medical purposes, and that the proposed blood level study at a third party Clinical Research Organization will demonstrate that the Company’s products have greater bioavailability than its competitors. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Risks and uncertainties include, but are not limited to, the risk that the federal administration in the United States declines to repeal legislation rendering the use and possession of cannabis illegal for any purpose, including medical purposes, and that the study conducted by a third party Clinical Research Organization demonstrates that the Company’s products do not have greater bioavailability. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

 

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The evolution of the cannabis industry in recent years continues to outperform market projections. While many attribute this unprecedented growth and positive trending to a focus on business-to-consumer models, some cannabis companies are finding significant successes leveraging white labeling partnerships to tap into a rapidly emerging marketplace that thrives on innovative business models and unique products for a growing consumer base

As the popularity of white labeling services amongst cannabis companies grows, especially in the production of fast-growing categories of value-added products like extracts, oils, edibles, and vapes, companies that are becoming an expert in co-manufacturing and have the ability to provide these services are establishing themselves as the leaders in the industry. Used as a means to expand SKU lines as well as revenue, white labeling in the cannabis industry offers companies unparalleled upside and potential for impressive profitability.

How do white labeling services work?

White labeling is a business practice that involves one company manufacturing a product, which is later sold and advertised under another company’s brand. These solutions are typically done in exchange for a flat fee or percentage of product sales depending on the terms of the agreement.

This INNspired article is brought to you by:

Ayurcann (CSE:AYUR) is a leading B2B post-harvest solution and provider focused on providing scalable custom processes and pharma-grade products to the medical cannabis industry in CanadaSend me an Investor Kit

This business-to-business solution offers a partnering company to attach their unique brand onto a “white label” product for marketing and sale to the final consumer and allows the manufacturing “white labeler” to potentially partner with different companies. Without the need to invest in infrastructure or technology. Cannabis companies can focus on building their brand and selling a wider range of products to a wide net of prospective customers.

Additionally, many also associate these white labeling solutions with toll processing, a practice in which one company provides the raw or partially processed product for another company to manufacture into a value-added product.

Access to extraction and packaging services through white label providers

White labeling services provide an ideal solution for companies who may not have the start-up capital to build a manufacturing facility, secure product licensing or have a difficult time getting a cannabis business off the ground. In these circumstances, partnering with a licensed processor that has established production and focused effort on creating a diversified range of high-quality cannabis products presents outstanding economic opportunities.

One leading example is  Ayurcann Holdings (CSE:AYUR), a B2B post-harvest solution provider focused on providing scalable custom processes and pharma-grade products to the recreational and medical cannabis industry in Canada. The company delivers a profitable business model of services and products. It operates three production divisions specializing in expert cannabis-based extraction and refinement, high-quality bulk oil sales and white label manufacturing.

White labeling options for cannabis companies

In an industry that is shifting its focus away from cultivation, more fully integrated companies delivering multiple verticals in cannabis processing and production offer an unparalleled investment opportunity that stands out from the rest. Major players in the cannabis white-labeling space offer unique exposure and retail footing that allow many companies to compete with established brands and quickly make an impact on consumers.

Ayuracann’s production offers full end-to-end outsourcing services, including proprietary product research & development, cannabis extraction & refinement and final production formulation and fulfillment. As a leading white labeling service provider, the company is focused on becoming the partner of choice for leading Canadian cannabis brands by delivering best-in-class, proprietary services, including ethanol extraction, formulation, product development and custom manufacturing.

Benefits of white labeling for cannabis companies

Data collected by Grand View Research projects the global legal cannabis market to be worth US$66.3 billion by 2025. While much of the cannabis product sold today is still the raw product, value-added consumer packaged goods are rapidly gaining significant traction throughout the cannabis industry.

White labeling services allow cannabis companies to capitalize on the latest and greatest cannabis consumer trends by expanding their portfolios to include high-demand products such as oil cartridges, extracts, topicals, CBD bath products and lotions, edibles and more. Without having to invest in the infrastructure, processing labs and manufacturing facilities required to make these products, companies can focus on releasing more products to an eager customer base. With an ever-evolving cannabis market, white label partnerships can give cannabis companies an edge over the competition.

While vertical integration can be a highly efficient strategy for large cannabis companies with the up-front capital to build the necessary infrastructure, companies without the resources to establish it take a huge risk by investing in operational and up-front costs. This includes time, building and equipment costs, license processing and finding specialized staff to grow and sustain the business.

Alternatively, outsourcing manufacturing allows a cannabis company to expand its product offerings, utilize quality formulations and establish its brand while reducing the financial risk associated with vertically integrating. Finding a compatible white labeling partnership means more time to build a brand and reach retailers and final consumers substantially faster. For cannabis companies who want to hit the ground running, white labeling offers the tools, expertise, and systems in place to make it happen.

Takeaway

Cannabis companies are using white labeling services to expand and diversify their product lines and tap into a market that is increasingly favoring value-added consumer packaged goods. For cannabis companies without fully vertically integrated operations, white-label partnerships with major players like Ayurcann Holdings offer exceptional economic efficiency and investing upside with minimized risks and infrastructural costs.

Keep reading... Show less

Dispensary reopening follows the opening of Trulieve’s 100 th Florida location

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), the largest multi-state operator (MSO) in the United States today announced the reopening of a dispensary in Lehigh Acres, Florida . The location is Trulieve’s 101 st in the state of Florida and was formerly branded as Harvest House of Cannabis.

Keep reading... Show less

Ayurcann Holdings Corp. (CSE: AYUR) (FSE: 3ZQ0) (the “Corporation” or “Ayurcann“), a Canadian cannabis extraction company specializing in the processing of cannabis and hemp to produce oils and various derivative products, announces it has retained Dolos Consultancy LTD (Dolos) and Apaton Group to manage shareholder communication, market intelligence and brand awareness for the company.

Dolos Consultancy LTD is one of the leading corporate strategy, intelligence gathering, investors analysis and capital advisories in the market. Dolos is working with a network of investors, family offices and venture capitalists, and is retained to support and accompany Ayurcann in both Investor relations and market intelligence.

Keep reading... Show less

Finalized study design and protocol mark major milestone to investigate natural Psilocybin

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract, previously announced on April 26, 2021 . This major milestone advances Numinus‘ investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office.

Keep reading... Show less